Allergan Buys MAP To Chart Migraine Franchise Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan partnered with MAP in 2011 for rights to commercialize Levadex for acute migraine in North America, but now will control 100% of the product’s revenue, creating a complementary product to Botox in chronic migraine. Levadex has an April 15 PDUFA date at FDA.
You may also be interested in...
Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs
Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.
Allergan Manufacturing Headaches Continue For Semprana
Inhalable acute migraine drug previously known as Levadex receives third “complete response” letter from FDA.
Allergan Manufacturing Headaches Continue For Semprana
Inhalable acute migraine drug previously known as Levadex receives third “complete response” letter from FDA.